Article Text

Download PDFPDF
Review: immediate antiplatelet therapy after acute ischaemic stroke reduces death or dependency and risk of recurrent stroke

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

P A Sandercock

Dr P A Sandercock, University of Edinburgh, Edinburgh, UK;


What is the efficacy and safety of immediate antiplatelet therapy after acute ischaemic stroke?


Included studies compared antiplatelet therapy, including aspirin, abciximab, heparin, and ticlopidine (started within 14 d of stroke) with placebo or no treatment in patients with acute ischaemic stroke. Studies of antiplatelet therapy after primary intracerebral or subarachnoid haemorrhage, or drugs with multiple modes of action (eg, piracetam, prostacyclin, and oxpentifylline) were excluded. Outcomes included death or dependence on others for activities of daily living 1 month after stroke, all-cause mortality, deep venous thrombosis, pulmonary embolism, recurrent stroke, and intracranial and extracranial haemorrhage.


Medline, EMBASE/Excerpta Medica, …

View Full Text


  • Source of funding: Wellcome Trust and Medical Research Council.